Darusentan
As of the edition of 20 October 2026, Darusentan is a small molecule: stopped in 2010; acts on EDNRA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2010
- Kind
- Small molecule
- Registered trials
- 5, 2 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EDNRA | Endothelin-1 receptor | P25101 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 4 | 2 | 0 | 2 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2004 to now |